Forventninger til regnskabsåret 2026/27

ChemoMetec guided FY2026/27 revenue to DKK 545-575 million, versus DKK 511.1 million in FY2025/26, implying growth of approximately 7%-12%. EBITDA is expected at DKK 300-315 million, up from DKK 281.3 million, implying roughly 7%-12% growth and continued high profitability. The outlook signals continued expansion for the cell-counting instrument supplier serving pharma, biotech and agricultural customers.

Analysis

The key equity question is not the growth rate but whether ChemoMetec can sustain its unusually high incremental profitability while re-accelerating instrument placements. At the midpoint, EBITDA margin modestly dilutes versus the prior year, implying that either sales mix, commercial investment, FX, or capacity costs are absorbing much of the incremental revenue. That is not inherently negative, but it limits upside to consensus-style operating leverage assumptions and makes the annual report’s disclosed assumptions—particularly recurring consumables growth and geographic mix—the critical diligence item.

Over the next 1-3 months, CHEMM should respond favorably if the outlook is above pre-release expectations, but a premium-quality medtech multiple will require evidence that biopharma customer budgets are converting into orders rather than merely stabilizing. Sartorius (SRT3), Danaher (DHR), Bio-Rad (BIO) and Revvity (RVTY) are imperfect but relevant read-throughs: a broad recovery in life-science tools would validate the demand backdrop, while weak order commentary from those larger peers would make a company-specific growth guide vulnerable. The 6-18 month structural upside rests on recurring consumables penetration from an expanding installed base; the principal risk is that instrument revenue is pulling forward demand and leaves growth dependent on lumpy large-account purchases.

Contrarianly, the guidance may be less bullish than the headline appears if investors had expected margin expansion after a strong prior year. With limited information on order backlog, book-to-bill, currency assumptions, and revenue split between instruments and consumables, there is insufficient basis to underwrite a durable earnings upgrade cycle today. Liquidity in a Copenhagen-listed small/mid-cap can amplify both a positive opening move and subsequent reversal once full-year detail is digested.

Key Decisions for Investors

• Maintain/watch CHEMM rather than chase the initial reaction; initiate a 3-6 month long only if management discloses recurring-consumables growth and order intake consistent with revenue landing above the DKK 575m top end. The upside case is renewed earnings-estimate revisions and multiple support; falsify on a cut to the EBITDA range or evidence of sub-guidance order conversion.
• For existing CHEMM longs, trim into a sharp post-release rally unless the full report demonstrates stable-to-expanding gross margin and improving book-to-bill. A midpoint EBITDA-margin decline of roughly 80bp means valuation upside is more dependent on revenue beat potential than on automatic operating leverage.
• Use SRT3, DHR, BIO and RVTY quarterly order commentary as a sector-demand monitor over the next two reporting cycles. Negative life-science tools organic-growth or bioprocessing guidance would be a risk trigger for CHEMM exposure, even if its near-term outlook remains unchanged.
• Set an alert for the annual-report disclosures on FX sensitivity, customer concentration, instrument versus consumables mix, and backlog. If these data are not sufficiently disclosed, treat CHEMM as a liquidity-sensitive single-name event position rather than a high-conviction sector recovery trade.